The Max Foundation’s 2019 Annual Report is Now Live

We are pleased to announce the publication of The Max Foundation’s 2019 Annual Report, showcasing the variety of achievements made possible with the support of our dedicated donors, partners, and global team.

Read the 2019 Annual Report

“Looking back at 2019 a common theme stands out: reaching new frontiers,” write The Max Foundation CEO Pat Garcia-Gonzalez and The Max Foundation Board President Paula Boultbee in the report.

These new frontiers include our program’s expansion into Mozambique, where chronic myeloid leukemia (CML) patients gained access to lifesaving treatment for the first time. We also grew our access to diagnostics initiatives that allowed patients to have access to affordable and local molecular tests. And through our patient services, we connected with thousands of patients and their caregivers worldwide through one-on-one support and community outreach.

In this report, we celebrate our organization’s achievements as well as patients’ milestones—each with a unique journey toward accessing treatment and care.

We’re thrilled to share with you the significance of our growth into new frontiers, and the impact it’s had on the patients we support worldwide. We hope you see yourself in each of our achievements and feel how your support directly contributes to the lives of patients and families who are now able to face their cancer with dignity and hope.

Read the 2019 Annual Report

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

The Max Foundation (Max) Expands Collaboration with Novartis to Include Access to Innovative Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH)
Max to immediately begin process to provide humanitarian access for Fabhalta® (iptacopan) in collaboration with its network of partner hematologists across 53 countries People living with the rare blood disease in low-middle income countries require frequent blood transfusions, experience debilitating symptoms of fatigue and without treatment may progress to more serious life-threatening diseases The Max….
Tanner Pharma Group Delivers on “Last Mile” in Global Health
Tanner Pharma Group will serve as the title sponsor for The Max Foundation’s 2018 campaign “Max Global Experience: Uganda,” an expedition to raise awareness and funds for increased cancer treatment access in Africa.
Welcoming Two New Board Members: Dr. Mika Matsuzaki and Dr. Susan M. Jerian
Please join us in welcoming Mika Matsuzaki, PhD, and Susan M. Jerian, MD to The Max Foundation Board of Directors.